The systemic nature of CKD

Nature Reviews Nephrology

Volumn 13, Issue 6, 2017, Pages 344-358

  Zoccali, Carmine ^a   Vanholder, Raymond ^b   Massy, Ziad A ^c,d,e,f,g   Ortiz, Alberto ^h   Sarafidis, Pantelis ⁱ   Dekker, Friedo W ^j   Fliser, Danilo ^k   Fouque, Denis ^l   Heine, Gunnar H ^k   Jager, Kitty J ^m   Kanbay, Mehmet ⁿ   Mallamaci, Francesca ^a   Parati, Gianfranco ^o   Rossignol, Patrick ^g,p,q,r   Wiecek, Andrzej ^s   London, Gerard ^t  

^a BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c HÔPITAL AMBROISE PARÉ   (France)

^d LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^e HÔPITAL PAUL BROUSSE   (France)

^f UNIVERSITÉ PARIS SACLAY   (France)

^g TOULOUSE UNIVERSITY HOSPITAL   (France)

^h UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

ⁱ Aristotle University of Thessaloniki   (Greece)

^j LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^k SAARLAND UNIVERSITY   (Germany)

^l UNIVERSITÉ LYON 1   (France)

^m European Renal Association European Dialysis and Transplant Association (ERA EDTA) Registry   (Netherlands)

ⁿ KOÇ UNIVERSITY   (Turkey)

^o UNIVERSITY OF MILANO BICOCCA   (Italy)

^p INSERM   (France)

^q UNIVERSITÉ DE LORRAINE   (France)

^r UNIVERSITY HOSPITAL OF NANCY   (France)

^s MEDICAL UNIVERSITY OF SILESIA   (Poland)

^t HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BONE MORPHOGENETIC PROTEIN; FIBROBLAST GROWTH FACTOR 23; GLUCOSE; MINERAL; SODIUM;

ALTERNATIVE ENERGY; AUTONOMIC NERVOUS SYSTEM; BONE DISEASE; CARDIOPULMONARY FUNCTION; CHRONIC KIDNEY FAILURE; ENERGY BALANCE; ENERGY CONSERVATION; GLUCOSE METABOLISM; HUMAN; HYPERTENSION; HYPOXIA; INFLAMMATION; INNATE IMMUNITY; INTEGRATION; KIDNEY DYSFUNCTION; LUNG DISEASE; METABOLOMICS; METAGENOMICS; MINERAL METABOLISM; NEUROPATHOLOGY; NONHUMAN; PATHOPHYSIOLOGY; PATIENT CARE; PERSONALIZED MEDICINE; PHENOTYPE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; SYSTEMIC DISEASE; SYSTEMS BIOLOGY; VASCULAR DISEASE; ANIMAL; BONE DISEASES; COMPLICATION; ENERGY METABOLISM; HEART DISEASES; IMMUNITY; IMMUNOLOGY; LUNG DISEASES; METABOLIC DISEASES; METABOLISM; NERVOUS SYSTEM DISEASES;

ANIMALS; BONE DISEASES; ENERGY METABOLISM; HEART DISEASES; HUMANS; IMMUNITY; INFLAMMATION; LUNG DISEASES; METABOLIC DISEASES; NERVOUS SYSTEM DISEASES; RENAL INSUFFICIENCY, CHRONIC;

EID: 85019266448     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2017.52     Document Type: Review

References (282)

1. KDIGO. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. Suppl. 3, 19-62 (2013).
2. Eckardt, K.-U. et al. Evolving importance of kidney disease: from subspecialty to global health burden. Lancet 382, 158-169 (2013).
3. MacCluer, J. W. et al. Heritability of measures of kidney disease among Zuni Indians: the Zuni Kidney Project. Am. J. Kidney Dis. 56, 289-302 (2010).
4. Barrett Bowling, C. et al. Age-specific associations of reduced estimated glomerular filtration rate with concurrent chronic kidney disease complications. Clin. J. Am. Soc. Nephrol. 6, 2822-2828 (2011).
5. Zoccali, C., Bolignano, D. & Mallamaci, F. in Oxord Textbook of Clinical Nephrology 4th edn Ch. 107 (eds Turner, N. N. et al.) 837-852 (Oxford Univ. Press, 2015).
6. Maarouf, O. H. et al. Paracrine Wnt1 drives interstitial fibrosis without inflammation by tubulointerstitial cross-talk. J. Am. Soc. Nephrol. 27, 781-790 (2015).
7. Abbas, N. A. et al. Cardiac troponins and renal function in nondialysis patients with chronic kidney disease. Clin. Chem. 51, 2059-2066 (2005).
8. Vickery, S. et al. B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with CKD: relationship to renal function and left ventricular hypertrophy. Am. J. Kidney Dis. 46, 610-620 (2005).
9. Tang, W. H. W. et al. Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival. Am. J. Cardiol. 108, 385-390 (2011).
10. Evenepoel, P., D'Haese, P. & Brandenburg, V. Sclerostin and DKK1: new players in renal bone and vascular disease. Kidney Int. 88, 235-240 (2015).
11. Ketteler, M. et al. Revisiting KDIGO clinical practice guideline on chronic kidney disease-mineral and bone disorder: a commentary from a Kidney Disease: Improving Global Outcomes controversies conference. Kidney Int. 87, 502-528 (2015).
12. Zoccali, C. et al. The complexity of the cardio-renal link: taxonomy, syndromes, and diseases. Kidney Int. Suppl. 1, 2-5 (2011).
13. Cozzolino, M. et al. Is chronic kidney disease-mineral bone disorder (CKD-MBD) really a syndrome? Nephrol. Dial. Transplant. 29, 1815-1820 (2014).
14. Brigandt, I. & Love, A. in The Stanford Encyclopedia of Philosophy (ed. Zalta, E. N.) (Stanford Univ., 2017).
15. Macdougall, I. C. et al. Beyond the cardiorenal anaemia syndrome: recognizing the role of iron deficiency. Eur. J. Heart Fail. 14, 882-886 (2012).
16. Beresford, M. J. Medical reductionism: lessons from the great philosophers. QJM 103, 721-724 (2010).
17. Hektoen International. Richard Bright, the father of nephrology. HekInt.org http://www. hektoeninternational.org/index.php?option=com- content&view=article&id=705 (2013).
18. Seldin, D. W., Carter, N. W. & Rector, F. C. in Strauss and Welt's Diseases of the Kidney Vol. 2 (eds Strauss, M. B. & Welt, L. G.) 211-272 (Little Brown Co., 1971).
19. Straub, R. H., Cutolo, M., Buttgereit, F. & Pongratz, G. Energy regulation and neuroendocrine-immune control in chronic inflammatory diseases. J. Intern. Med. 267, 543-560 (2010).
20. Manning, P. J. et al. Postprandial cytokine concentrations and meal composition in obese and lean women. Obesity (Silver Spring) 16, 2046-2052 (2008).
21. Walford, R. L., Harris, S. B. & Gunion, M. W. The calorically restricted low-fat nutrient-dense diet in Biosphere 2 significantly lowers blood glucose, total leukocyte count, cholesterol, and blood pressure in humans. Proc. Natl Acad. Sci. USA 89, 11533-11537 (1992).
22. Maciver, N. J. et al. Glucose metabolism in lymphocytes is a regulated process with significant effects on immune cell function and survival. J. Leukoc. Biol. 84, 949-957 (2008).
23. Frauwirth, K. A. & Thompson, C. B. Regulation of T lymphocyte metabolism. J. Immunol. 172, 4661-4665 (2004).
24. Mauvais-Jarvis, F. Estrogen and androgen receptors: regulators of fuel homeostasis and emerging targets for diabetes and obesity. Trends Endocrinol. Metab. 22, 24-33 (2011).
25. Ducy, P. The role of osteocalcin in the endocrine cross-talk between bone remodelling and energy metabolism. Diabetologia 54, 1291-1297 (2011).
26. Moore, M. C. et al. Effect of hepatic denervation on peripheral insulin sensitivity in conscious dogs. Am. J. Physiol. Endocrinol. Metab. 282, E286-E296 (2002).
27. Christiansen, J. J. et al. Effects of cortisol on carbohydrate, lipid, and protein metabolism: studies of acute cortisol withdrawal in adrenocortical failure. J. Clin. Endocrinol. Metab. 92, 3553-3559 (2009).
28. Jones, B. J., Tan, T. & Bloom, S. R. Minireview: glucagon in stress and energy homeostasis. Endocrinology 153, 1049-1054 (2012).
29. Báez-Pagán, C. A., Delgado-Vélez, M. & Lasalde-Dominicci, J. A. Activation of the macrophage α7 nicotinic acetylcholine receptor and control of inflammation. J. Neuroimmune Pharmacol. 10, 468-476 (2015).
30. Andersson, U. & Tracey, K. J. Neural reflexes in inflammation and immunity. J. Exp. Med. 209, 1057-1068 (2012).
31. Scherrer, U. & Sartori, C. Insulin as a vascular and sympathoexcitatory hormone: implications for blood pressure regulation, insulin sensitivity, and cardiovascular morbidity. Circulation 96, 4104-4113 (1997).
32. Rui, L. Energy metabolism in the liver. Compr. Physiol. 4, 177-197 (2014).
33. Härle, P., Möbius, D., Carr, D. J. J., Schölmerich, J. & Straub, R. H. An opposing time-dependent immune-modulating effect of the sympathetic nervous system conferred by altering the cytokine profile in the local lymph nodes and spleen of mice with type II collagen-induced arthritis. Arthritis Rheum. 52, 1305-1313 (2005).
34. Mehrotra, R. et al. Serum fetuin-A in nondialyzed patients with diabetic nephropathy: relationship with coronary artery calcification. Kidney Int. 67, 1070-1077 (2005).
35. Gupta, J. et al. Association between albuminuria, kidney function, and inflammatory biomarker profile in CKD in CRIC. Clin. J. Am. Soc. Nephrol. 7, 1938-1946 (2012).
36. Cottone, S. et al. Relationship of fetuin-A with glomerular filtration rate and endothelial dysfunction in moderate-severe chronic kidney disease. J. Nephrol. 23, 62-69 (2010).
37. Stenvinkel, P. & Larsson, T. E. Chronic kidney disease: a clinical model of premature aging. Am. J. Kidney Dis. 62, 339-351 (2013).
38. Schindler, R. Causes and therapy of microinflammation in renal failure. Nephrol. Dial. Transplant. 19, 34-40 (2004).
39. Levey, A. S. et al. Chronic kidney disease as a global public health problem: approaches and initiatives-a position statement from Kidney Disease Improving Global Outcomes. Kidney Int. 72, 247-259 (2007).
40. Akar, H., Akar, G. C., Carrero, J. J., Stenvinkel, P. & Lindholm, B. Systemic consequences of poor oral health in chronic kidney disease patients. Clin. J. Am. Soc. Nephrol. 6, 218-226 (2011).
41. Locatelli, F. et al. Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol. Dial. Transplant. 18, 1272-1280 (2003).
42. Gardner, S. E., Humphry, M., Bennett, M. R. & Clarke, M. C. H. Senescent vascular smooth muscle cells drive inflammation through an interleukin-1α-dependent senescence-associated secretory phenotype. Arterioscler. Thromb. Vasc. Biol. 35, 1963-1974 (2015).
43. Carrero, J. J. et al. Low serum testosterone increases mortality risk among male dialysis patients. J. Am. Soc. Nephrol. 20, 613-620 (2009).
44. Vlassara, H. et al. Role of oxidants/inflammation in declining renal function in chronic kidney disease and normal aging. Kidney Int. Suppl. 76, S3-S11 (2009).
45. Sun, C.-Y., Hsu, H.-H. & Wu, M.-S. p-Cresol sulfate and indoxyl sulfate induce similar cellular inflammatory gene expressions in cultured proximal renal tubular cells. Nephrol. Dial. Transplant. 28, 70-78 (2013).
46. Rao, A. K. et al. Left atrial volume is associated with inflammation and atherosclerosis in patients with kidney disease. Echocardiography 25, 264-269 (2008).
47. de Nadai, T. R. et al. Metabolic acidosis treatment as part of a strategy to curb inflammation. Int. J. Inflam. 2013, 601424 (2013).
48. Viaene, L. et al. Inflammation and the bone-vascular axis in end-stage renal disease. Osteoporos. Int. 27, 489-497 (2016).
49. Aghagolzadeh, P. et al. Calcification of vascular smooth muscle cells is induced by secondary calciprotein particles and enhanced by tumor necrosis factor-α. Atherosclerosis 251, 404-414 (2016).
50. Underwood, C. F. et al. Uraemia: an unrecognized driver of central neurohumoral dysfunction in chronic kidney disease? Acta Physiol. (Oxf.) 219, 305-323 (2016).
51. Thomas, S. S., Zhang, L. & Mitch, W. E. Molecular mechanisms of insulin resistance in chronic kidney disease. Kidney Int. 88, 1233-1239 (2015).
52. Meyring-Wösten, A. et al. Intradialytic hypoxemia and clinical outcomes in patients on hemodialysis. Clin. J. Am. Soc. Nephrol. 11, 616-625 (2016).
53. Spoto, B. et al. Association of IL-6 and a functional polymorphism in the IL-6 gene with cardiovascular events in patients with CKD. Clin. J. Am. Soc. Nephrol. 10, 232-240 (2015).
54. Stenvinkel, P. et al. Impact of inflammation on epigenetic DNA methylation-a novel risk factor for cardiovascular disease? J. Intern. Med. 261, 488-499 (2007).
55. Silva, J. E. Thyroid hormone control of thermogenesis and energy balance. Thyroid 5, 481-492 (1995).
56. Zoccali, C., Tripepi, G., Cutrupi, S., Pizzini, P. & Mallamaci, F. Low triiodothyronine: a new facet of inflammation in end-stage renal disease. J. Am. Soc. Nephrol. 16, 2789-2795 (2005).
57. Meuwese, C. L., Dekkers, O. M., Stenvinkel, P., Dekker, F. W. & Carrero, J. J. Nonthyroidal illness and the cardiorenal syndrome. Nat. Rev. Nephrol. 9, 599-609 (2013).
58. Levick, S. P., Murray, D. B., Janicki, J. S. & Brower, G. L. Sympathetic nervous system modulation of inflammation and remodeling in the hypertensive heart. Hypertension 55, 270-276 (2010).
59. Mafra, D. et al. Role of altered intestinal microbiota in systemic inflammation and cardiovascular disease in chronic kidney disease. Future Microbiol. 9, 399-410 (2014).
60. Koppe, L., Mafra, D. & Fouque, D. Probiotics and chronic kidney disease. Kidney Int. 88, 1-9 (2015).
61. Holzer, P. & Farzi, A. Neuropeptides and the microbiota-gut-brain axis. Adv. Exp. Med. Biol. 817, 195-219 (2014).
62. Lai, H. L., Kartal, J. & Mitsnefes, M. Hyperinsulinemia in pediatric patients with chronic kidney disease: the role of tumor necrosis factor-α. Pediatr. Nephrol. 22, 1751-1756 (2007).
63. Landau, M. et al. Correlates of insulin resistance in older individuals with and without kidney disease. Nephrol. Dial. Transplant. 26, 2814-2819 (2011).
64. Mallamaci, F., Tripepi, G. & Zoccali, C. Leptin in end stage renal disease (ESRD): a link between fat mass, bone and the cardiovascular system. J. Nephrol. 18, 464-468 (2005).
65. Yoo, D. E. et al. Low circulating adiponectin levels are associated with insulin resistance in non-obese peritoneal dialysis patients. Endocr. J. 59, 685-695 (2012).
66. Landsberg, L. & Young, J. B. Fasting, feeding and regulation of the sympathetic nervous system. N. Engl. J. Med. 298, 1295-1301 (1978).
67. Yano, Y. et al. Synergistic effect of chronic kidney disease and high circulatory norepinephrine level on stroke risk in Japanese hypertensive patients. Atherosclerosis 219, 273-279 (2011).
68. Fouque, D. et al. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int. 73, 391-398 (2008).
69. Kalantar-Zadeh, K., Ikizler, T. A., Block, G., Avram, M. M. & Kopple, J. D. Malnutrition-inflammation complex syndrome in dialysis patients: causes and consequences. Am. J. Kidney Dis. 42, 864-881 (2003).
70. Gupta, J. et al. Association between inflammation and cardiac geometry in chronic kidney disease: findings from the CRIC study. PLoS ONE 10, e0124772 (2015).
71. Zoccali, C. et al. Fibrinogen, inflammation and concentric left ventricular hypertrophy in chronic renal failure. Eur. J. Clin. Invest. 33, 561-566 (2003).
72. Zoccali, C. et al. Norepinephrine and concentric hypertrophy in patients with end-stage renal disease. Hypertension 40, 41-46 (2002).
73. Zoccali, C. et al. Neuropeptide Y, left ventricular mass and function in patients with end stage renal disease. J. Hypertens. 21, 1355-1362 (2003).
74. Zoccali, C. et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 105, 1354-1359 (2002).
75. Zoccali, C. et al. Prospective study of neuropeptide Y as an adverse cardiovascular risk factor in end-stage renal disease. J. Am. Soc. Nephrol. 14, 2611-2617 (2003).
76. Eltzschig, H. K. & Carmeliet, P. Hypoxia and inflammation. N. Engl. J. Med. 364, 656-665 (2011).
77. O'Riordan, E. et al. Chronic NOS inhibition actuates endothelial-mesenchymal transformation. Am. J. Physiol. Heart Circ. Physiol. 292, H285-H294 (2007).
78. Kang, D.-H. et al. Role of the microvascular endothelium in progressive renal disease. J. Am. Soc. Nephrol. 13, 806-816 (2002).
79. Tanaka, T. & Nangaku, M. Angiogenesis and hypoxia in the kidney. Nat. Rev. Nephrol. 9, 211-222 (2013).
80. Hussain, S. et al. Outcome among patients with acute renal failure needing continuous renal replacement therapy: a single center study. Hemodial. Int. 13, 205-214 (2009).
81. Bollée, G. et al. Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib. Nephrol. Dial. Transplant. 24, 682-685 (2009).
82. Massy, Z. A., Stenvinkel, P. & Drueke, T. B. The role of oxidative stress in chronic kidney disease. Semin. Dial. 22, 405-408 (2009).
83. Kapitsinou, P. P. & Haase, V. H. Molecular mechanisms of ischemic preconditioning in the kidney. Am. J. Physiol. Renal Physiol. 309, F821-F834 (2015).
84. Tanaka, T. Expanding roles of the hypoxia-response network in chronic kidney disease. Clin. Exp. Nephrol. 20, 835-844 (2016).
85. Tanaka, T., Yamaguchi, J., Higashijima, Y. & Nangaku, M. Indoxyl sulfate signals for rapid mRNA stabilization of Cbp/p300-interacting transactivator with Glu/Asp-rich carboxy-terminal domain 2 (CITED2) and suppresses the expression of hypoxia-inducible genes in experimental CKD and uremia. FASEB J. 27, 4059-4075 (2013).
86. Sun, C.-Y., Chang, S.-C. & Wu, M.-S. Suppression of Klotho expression by protein-bound uremic toxins is associated with increased DNA methyltransferase expression and DNA hypermethylation. Kidney Int. 81, 640-650 (2012).
87. Deng, A. et al. Renal protection in chronic kidney disease: hypoxia-inducible factor activation versus angiotensin II blockade. Am. J. Physiol. Renal Physiol. 299, F1365-F1373 (2010).
88. Maxwell, P. H. & Eckardt, K.-U. HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond. Nat. Rev. Nephrol. 12, 157-168 (2015).
89. Munoz Mendoza, J. et al. Fibroblast growth factor 23 and Inflammation in CKD. Clin. J. Am. Soc. Nephrol. 7, 1155-1162 (2012).
90. Fliser, D. et al. Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease. Kidney Int. 53, 1343-1347 (1998).
91. de Boer, I. H. et al. Impaired glucose and insulin homeostasis in moderate-severe CKD. J. Am. Soc. Nephrol. 27, 2861-2871 (2016).
92. DeFronzo, R. A. et al. Insulin resistance in uremia. J. Clin. Invest. 67, 563-568 (1981).
93. Schenk, S., Saberi, M. & Olefsky, J. M. Insulin sensitivity: modulation by nutrients and inflammation. J. Clin. Invest. 118, 2992-3002 (2008).
94. Djiogue, S. et al. Insulin resistance and cancer: the role of insulin and IGFs. Endocr. Relat. Cancer 20, R1-R17 (2013).
95. Giles, J. T. et al. Insulin resistance in rheumatoid arthritis: disease-related indicators and associations with the presence and progression of subclinical atherosclerosis. Arthritis Rheumatol. 67, 626-636 (2015).
96. Hotamisligil, G. S. et al. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha-and obesity-induced insulin resistance. Science 271, 665-668 (1996).
97. Senn, J. J., Klover, P. J., Nowak, I. A. & Mooney, R. A. Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 51, 3391-3399 (2002).
98. Yadav, A., Kataria, M. A., Saini, V. & Yadav, A. Role of leptin and adiponectin in insulin resistance. Clin. Chim. Acta 417, 80-84 (2013).
99. Muse, E. D. et al. Role of resistin in diet-induced hepatic insulin resistance. J. Clin. Invest. 114, 232-239 (2004).
100. Straub, R. H. & Besedovsky, H. O. Integrated evolutionary, immunological, and neuroendocrine framework for the pathogenesis of chronic disabling inflammatory diseases. FASEB J. 17, 2176-2183 (2003).
101. Straub, R. H. & Schradin, C. Chronic inflammatory systemic diseases: an evolutionary trade-off between acutely beneficial but chronically harmful programs. Evol. Med. Public Health 2016, 37-51 (2016).
102. He, J. et al. Urinary sodium and potassium excretion and CKD progression. J. Am. Soc. Nephrol. 27, 1202-1212 (2015).
103. Mills, K. T. et al. Sodium excretion and the risk of cardiovascular disease in patients with chronic kidney disease. JAMA 315, 2200-2210 (2016).
104. Rodríguez-Iturbe, B., Vaziri, N. D., Herrera-Acosta, J. & Johnson, R. J. Oxidative stress, renal infiltration of immune cells, and salt-sensitive hypertension: all for one and one for all. Am. J. Physiol. Renal Physiol. 286, F606-F616 (2004).
105. + as a regulator of immunity. Pediatr. Nephrol. 32, 201-210 (2016).
106. Machnik, A. et al. Macrophages regulate salt-dependent volume and blood pressure by a vascular endothelial growth factor-C-dependent buffering mechanism. Nat. Med. 15, 545-552 (2009).
107. Lee, N. K. An evolving integrative physiology: skeleton and energy metabolism. BMB Rep. 43, 579-583 (2010).
108. Amanzadeh, J. & Reilly, R. F. Hypophosphatemia: an evidence-based approach to its clinical consequences and management. Nat. Clin. Pract. Nephrol. 2, 136-148 (2006).
109. Tonelli, M. et al. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 112, 2627-2633 (2005).
110. Faul, C. et al. FGF23 induces left ventricular hypertrophy. J. Clin. Invest. 121, 4393-4408 (2011).
111. Ferron, M. & Lacombe, J. Regulation of energy metabolism by the skeleton: osteocalcin and beyond. Arch. Biochem. Biophys. 561, 137-146 (2014).
112. Lee, N. K. et al. Endocrine regulation of energy metabolism by the skeleton. Cell 130, 456-469 (2007).
113. Rix, M., Andreassen, H., Eskildsen, P., Langdahl, B. & Olgaard, K. Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure. Kidney Int. 56, 1084-1093 (1999).
114. Hinoi, E. et al. The sympathetic tone mediates leptin's inhibition of insulin secretion by modulating osteocalcin bioactivity. J. Cell Biol. 183, 1235-1242 (2008).
115. Hong, S.-H. et al. Changes in serum osteocalcin are not associated with changes in glucose or insulin for osteoporotic patients treated with bisphosphonate. J. Bone Metab. 20, 37-41 (2013).
116. Schwartz, A. V. et al. Effects of antiresorptive therapies on glucose metabolism: results from the FIT, HORIZON-PFT, and FREEDOM trials. J. Bone Miner. Res. 28, 1348-1354 (2013).
117. Vervloet, M. G. et al. Bone: a new endocrine organ at the heart of chronic kidney disease and mineral and bone disorders. Lancet Diabetes Endocrinol. 2, 427-436 (2014).
118. Holden, R. M. et al. Vitamins K and D status in stages 3-5 chronic kidney disease. Clin. J. Am. Soc. Nephrol. 5, 590-597 (2010).
119. McCabe, K. M. et al. Dietary vitamin K and therapeutic warfarin alter the susceptibility to vascular calcification in experimental chronic kidney disease. Kidney Int. 83, 835-844 (2013).
120. Okuno, S. et al. Significant inverse relationship between serum undercarboxylated osteocalcin and glycemic control in maintenance hemodialysis patients. Osteoporos. Int. 24, 605-612 (2013).
121. Patterson-Buckendahl, P. Osteocalcin is a stress-responsive neuropeptide. Endocr. Regul. 45, 99-110 (2011).
122. Kawai, M., Kinoshita, S., Shimba, S., Ozono, K. & Michigami, T. Sympathetic activation induces skeletal Fgf23 expression in a circadian rhythm-dependent manner. J. Biol. Chem. 289, 1457-1466 (2014).
123. Grabner, A. et al. Activation of cardiac fibroblast growth factor receptor 4 causes left ventricular hypertrophy. Cell Metab. 22, 1020-1032 (2015).
124. Gutiérrez, O. M. et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 119, 2545-2552 (2009).
125. Dai, B. et al. A comparative transcriptome analysis identifying FGF23 regulated genes in the kidney of a mouse CKD model. PLoS ONE 7, e44161 (2012).
126. Wojcik, M. et al. The association of FGF23 levels in obese adolescents with insulin sensitivity. J. Pediatr. Endocrinol. Metab. 25, 687-690 (2012).
127. Mirza, M. A. I. et al. Circulating fibroblast growth factor-23 is associated with fat mass and dyslipidemia in two independent cohorts of elderly individuals. Arterioscler. Thromb. Vasc. Biol. 31, 219-227 (2011).
128. Scialla, J. J. et al. Fibroblast growth factor-23 and cardiovascular events in CKD. J. Am. Soc. Nephrol. 25, 349-360 (2014).
129. Xie, J., Yoon, J., An, S.-W., Kuro-o, M. & Huang, C.-L. Soluble klotho protects against uremic cardiomyopathy independently of fibroblast growth factor 23 and phosphate. J. Am. Soc. Nephrol. 26, 1150-1160 (2015).
130. Fliser, D. et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J. Am. Soc. Nephrol. 18, 2600-2608 (2007).
131. Scialla, J. J. et al. Mineral metabolites and CKD progression in African Americans. J. Am. Soc. Nephrol. 24, 125-135 (2013).
132. Tripepi, G. et al. Competitive interaction between fibroblast growth factor 23 and asymmetric dimethylarginine in patients with CKD. J. Am. Soc. Nephrol. 26, 1-10 (2014).
133. Sanz, A. B. et al. TWEAK and the progression of renal disease: clinical translation. Nephrol. Dial. Transplant. 29 (Suppl. 1), i54-i62 (2014).
134. David, V. et al. Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production. Kidney Int. 89, 135-146 (2015).
135. Dounousi, E. et al. Intact FGF23 and αklotho during acute inflammation/sepsis in CKD patients. Eur. J. Clin. Invest. 46, 234-241 (2016).
136. Rossaint, J. et al. FGF23 signaling impairs neutrophil recruitment and host defense during CKD. 126, 962-974 (2016).
137. Silswal, N. et al. FGF23 directly impairs endothelium-dependent vasorelaxation by increasing superoxide levels and reducing nitric oxide bioavailability. Am. J. Physiol. Endocrinol. Metab. 307, E426-E436 (2014).
138. Dounousi, E. et al. Effect of inflammation by acute sepsis on intact fibroblast growth factor 23 (iFGF23) and asymmetric dimethyl arginine (ADMA) in ckd patients. Nutr. Metab. Cardiovasc. Dis. 26, 80-83 (2015).
139. Lopez, A. et al. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit. Care Med. 32, 21-30 (2004).
140. London, G. M., Marchais, S. J., Guérin, A. P. & de Vernejoul, M.-C. Ankle-brachial index and bone turnover in patients on dialysis. J. Am. Soc. Nephrol. 26, 1-8 (2014).
141. Ng, K. W. Regulation of glucose metabolism and the skeleton. Clin. Endocrinol. (Oxf.) 75, 147-155 (2011).
142. Zoccali, C. et al. Leptin and biochemical markers of bone turnover in dialysis patients. J. Nephrol. 17, 253-260 (2004).
143. Grgurevic, L., Christensen, G. L., Schulz, T. J. & Vukicevic, S. Bone morphogenetic proteins in inflammation, glucose homeostasis and adipose tissue energy metabolism. Cytokine Growth Factor Rev. 27, 105-118 (2016).
144. Luttropp, K. et al. Genotypic and phenotypic predictors of inflammation in patients with chronic kidney disease. Nephrol. Dial. Transplant. 31, 2033-2040 (2016).
145. Li, X., Yang, H.-Y. & Giachelli, C. M. BMP-2 promotes phosphate uptake, phenotypic modulation, and calcification of human vascular smooth muscle cells. Atherosclerosis 199, 271-277 (2008).
146. Smith, E. R. et al. Phosphorylated fetuin-A-containing calciprotein particles are associated with aortic stiffness and a procalcific milieu in patients with pre-dialysis CKD. Nephrol. Dial. Transplant. 27, 1957-1966 (2012).
147. Muñoz-Félix, J. M., González-Núñez, M., Martínez-Salgado, C. & López-Novoa, J. M. TGF-β/BMP proteins as therapeutic targets in renal fibrosis. Where have we arrived after 25 years of trials and tribulations? Pharmacol. Ther. 156, 44-58 (2015).
148. Massy, Z. A. & Drueke, T. B. Activin receptor IIA ligand trap in chronic kidney disease: 1 drug to prevent 2 complications-or even more? Kidney Int. 89, 1180-1182 (2016).
149. Gruden, G., Landi, A. & Bruno, G. Natriuretic peptides, heart, and adipose tissue: new findings and future developments for diabetes research. Diabetes Care 37, 2899-2908 (2014).
150. Engeli, S. et al. Natriuretic peptides enhance the oxidative capacity of human skeletal muscle. J. Clin. Invest. 122, 4675-4679 (2012).
151. Chiurchiù, V. et al. Brain natriuretic peptide (BNP) regulates the production of inflammatory mediators in human THP-1 macrophages. Regul. Pept. 148, 26-32 (2008).
152. Li, D. et al. Efficacy of B-type natriuretic peptide is coupled to phosphodiesterase 2A in cardiac sympathetic neurons. Hypertension 66, 190-198 (2015).
153. Hagiwara, H. et al. Autocrine regulation of rat chondrocyte proliferation by natriuretic peptide C and its receptor, natriuretic peptide receptor-B. J. Biol. Chem. 269, 10729-10733 (1994).
154. Suda, M. et al. C-type natriuretic peptide as an autocrine/paracrine regulator of osteoblast. Evidence for possible presence of bone natriuretic peptide system. Biochem. Biophys. Res. Commun. 223, 1-6 (1996).
155. Holliday, L. S., Dean, A. D., Greenwald, J. E. & Glucks, S. L. C-type natriuretic peptide increases bone resorption in 1, 25-dihydroxyvitamin D3-stimulated mouse bone marrow cultures. J. Biol. Chem. 270, 18983-18989 (1995).
156. Suda, M. et al. Skeletal overgrowth in transgenic mice that overexpress brain natriuretic peptide. Proc. Natl Acad. Sci. USA 95, 2337-2342 (1998).
157. Zoccali, C. et al. Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients. J. Am. Soc. Nephrol. 12, 1508-1515 (2001).
158. Gunta, S. S., Thadhani, R. I. & Mak, R. H. The effect of vitamin D status on risk factors for cardiovascular disease. Nat. Rev. Nephrol. 9, 337-347 (2013).
159. Johal, M. & Levin, A. Vitamin D and parathyroid hormone in general populations: understandings in 2009 and applications to chronic kidney disease. Clin. J. Am. Soc. Nephrol. 4, 1508-1514 (2009).
160. Koppe, L. et al. Insulin resistance in chronic kidney disease: new lessons from experimental models. Nephrol. Dial. Transplant. 29, 1666-1674 (2014).
161. Vanholder, R. & Glorieux, G. The intestine and the kidneys: a bad marriage can be hazardous. Clin. Kidney J. 8, 168-179 (2015).
162. Wong, J. et al. Expansion of urease-and uricase-containing, indole-and p-cresol-forming and contraction of short-chain fatty acid-producing intestinal microbiota in ESRD. Am. J. Nephrol. 39, 230-237 (2014).
163. Vaziri, N. D. et al. Chronic kidney disease alters intestinal microbial flora. Kidney Int. 83, 308-315 (2012).
164. Sumida, K. et al. Constipation and incident CKD. J. Am. Soc. Nephrol. http://dx.doi.org/10.1681/ASN.2016060656 (2016).
165. Servillo, L., Giovane, A., Cautela, D., Castaldo, D. & Balestrieri, M. L. The methylarginines NMMA, ADMA, and SDMA are ubiquitous constituents of the main vegetables of human nutrition. Nitric Oxide 30, 43-48 (2013).
166. Koschinsky, T. et al. Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc. Natl Acad. Sci. USA 94, 6474-6479 (1997).
167. Schepers, E. et al. Symmetric dimethylarginine as a proinflammatory agent in chronic kidney disease. Clin. J. Am. Soc. Nephrol. 6, 2374-2383 (2011).
168. Ravani, P. et al. Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J. Am. Soc. Nephrol. 16, 2449-2455 (2005).
169. Zoccali, C. et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 358, 2113-2117 (2001).
170. Tripepi, G. et al. Inflammation and asymmetric dimethylarginine for predicting death and cardiovascular events in ESRD patients. Clin. J. Am. Soc. Nephrol. 6, 1714-1721 (2011).
171. Baumann, M. Role of advanced glycation end products in hypertension and cardiovascular risk: human studies. J. Am. Soc. Hypertens. 6, 427-435 (2012).
172. Wikoff, W. R. et al. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc. Natl Acad. Sci. USA 106, 3698-3703 (2009).
173. Poesen, R. et al. Renal clearance and intestinal generation of p-cresyl sulfate and indoxyl sulfate in CKD. Clin. J. Am. Soc. Nephrol. 8, 1508-1514 (2013).
174. Aronov, P. A. et al. Colonic contribution to uremic solutes. J. Am. Soc. Nephrol. 22, 1769-1776 (2011).
175. Tanaka, H. et al. p-cresyl sulfate induces osteoblast dysfunction through activating JNK and p38 MAPK pathways. Bone 56, 347-354 (2013).
176. Hirata, J. et al. Indoxyl sulfate exacerbates low bone turnover induced by parathyroidectomy in young adult rats. Bone 79, 252-258 (2015).
177. Pletinck, A. et al. Protein-bound uremic toxins stimulate crosstalk between leukocytes and vessel wall. J. Am. Soc. Nephrol. 24, 1981-1994 (2013).
178. Vanholder, R., Schepers, E., Pletinck, A., Nagler, E. V. & Glorieux, G. The uremic toxicity of indoxyl sulfate and p-cresyl sulfate: a systematic review. J. Am. Soc. Nephrol. 25, 1-11 (2014).
179. Piccoli, G. B. et al. Low protein diets in patients with chronic kidney disease: a bridge between mainstream and complementary-alternative medicines? BMC Nephrol. 17, 76 (2016).
180. Schulman, G. et al. Randomized placebo-controlled EPPIC trials of AST-120 in CKD. J. Am. Soc. Nephrol. 26, 1732-1746 (2015).
181. Cha, R.-H. et al. A randomized, controlled trial of oral intestinal sorbent AST-120 on renal function deterioration in patients with advanced renal dysfunction. Clin. J. Am. Soc. Nephrol. 11, 559-567 (2016).
182. Poesen, R. et al. Cardiovascular disease relates to intestinal uptake of p-cresol in patients with chronic kidney disease. BMC Nephrol. 15, 87 (2014).
183. McCafferty, K. et al. Intestinal microbiota determine severity of myocardial infarction in rats. FASEB J. 26, 1727-1735 (2012).
184. Wang, Z. et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472, 57-63 (2011).
185. Mueller, D. M. et al. Plasma levels of trimethylamine-N-oxide are confounded by impaired kidney function and poor metabolic control. Atherosclerosis 243, 638-644 (2015).
186. Tang, W. H. W. et al. Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circ. Res. 116, 448-455 (2015).
187. Semba, R. D. et al. The association of serum choline with linear growth failure in young children from rural Malawi. Am. J. Clin. Nutr. 104, 191-197 (2016).
188. Galland, L. The gut microbiome and the brain. J. Med. Food 17, 1261-1272 (2014).
189. Brown, J. M. & Hazen, S. L. The gut microbial endocrine organ: bacterially derived signals driving cardiometabolic diseases. Annu. Rev. Med. 66, 343-359 (2015).
190. Zhu, W. et al. Gut microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk. Cell 165, 111-124 (2016).
191. Zgoda-Pols, J. R. et al. Metabolomics analysis reveals elevation of 3-indoxyl sulfate in plasma and brain during chemically-induced acute kidney injury in mice: investigation of nicotinic acid receptor agonists. Toxicol. Appl. Pharmacol. 255, 48-56 (2011).
192. Smith, P. A. The tantalizing links between gut microbes and the brain. Nature 526, 312-314 (2015).
193. Dou, L. et al. The cardiovascular effect of the uremic solute indole-3 acetic acid. J. Am. Soc. Nephrol. 26, 876-887 (2015).
194. Shivanna, S. et al. The Aryl hydrocarbon receptor is a critical regulator of tissue factor stability and an antithrombotic target in uremia. J. Am. Soc. Nephrol. 27, 189-201 (2016).
195. Jankowski, J. et al. Increased plasma phenylacetic acid in patients with end-stage renal failure inhibits iNOS expression. J. Clin. Invest. 112, 256-264 (2003).
196. Rossi, M. et al. Synbiotics easing renal failure by improving gut microbiology (SYNERGY): a randomized trial. Clin. J. Am. Soc. Nephrol. 11, 1-9 (2016).
197. Garneata, L., Stancu, A., Dragomir, D., Stefan, G. & Mircescu, G. Ketoanalogue-supplemented vegetarian very low-protein diet and CKD progression. J. Am. Soc. Nephrol. 27, 2164-2176 (2016).
198. Simkhovich, B. Z., Kleinman, M. T. & Kloner, R. A. Air pollution and cardiovascular injury. J. Am. Coll. Cardiol. 52, 719-726 (2008).
199. Sponholtz, T. R., Sandler, D. P., Parks, C. G. & Applebaum, K. M. Occupational exposures and chronic kidney disease: possible associations with endotoxin and ultrafine particles. Am. J. Ind. Med. 59, 1-11 (2016).
200. Cutz, E. Hyperplasia of pulmonary neuroendocrine cells in infancy and childhood. Semin. Diagn. Pathol. 32, 420-437 (2015).
201. Whitsett, J. A. & Morrisey, E. E. Inflammation. Modulating pulmonary inflammation. Science 351, 662-663 (2016).
202. Gu, X. et al. Chemosensory functions for pulmonary neuroendocrine cells. Am. J. Respir. Cell Mol. Biol. 50, 637-646 (2014).
203. Kasacka, I. Quantitative characteristics of calcitonin-producing cells in the thyroid and lungs of uremic rats. Folia Histochem. Cytobiol. 46, 525-530 (2008).
204. Navaneethan, S. D. et al. Obstructive and restrictive lung function measures and CKD: National Health and Nutrition Examination Survey (NHANES) 2007-2012. Am. J. Kidney Dis. 68, 414-421 (2016).
205. Grassi, G. et al. Sympathetic nerve traffic and asymmetric dimethylarginine in chronic kidney disease. Clin. J. Am. Soc. Nephrol. 6, 2620-2627 (2011).
206. Hurtado, A., Escudero, E., Pando, J., Sharma, S. & Johnson, R. J. Cardiovascular and renal effects of chronic exposure to high altitude. Nephrol. Dial. Transplant. 27 (Suppl. 4), iv11-iv16 (2012).
207. Mannino, D. M., Ford, E. S. & Redd, S. C. Obstructive and restrictive lung disease and markers of inflammation: data from the Third National Health and Nutrition Examination. Am. J. Med. 114, 758-762 (2003).
208. Scheel, P. J., Liu, M. & Rabb, H. Uremic lung: new insights into a forgotten condition. Kidney Int. 74, 849-851 (2008).
209. Stenvinkel, P. & Alvestrand, A. Inflammation in end-stage renal disease: sources, consequences, and therapy. Semin. Dial. 15, 329-337 (2002).
210. Tripepi, G., Mallamaci, F. & Zoccali, C. Inflammation markers, adhesion molecules, and all-cause and cardiovascular mortality in patients with ESRD: searching for the best risk marker by multivariate modeling. J. Am. Soc. Nephrol. 16 (Suppl. 1), S83-S88 (2005).
211. Zoccali, C. et al. Lung congestion as a risk factor in end-stage renal disease. Blood Purif. 36, 184-191 (2013).
212. Zoccali, C. et al. Pulmonary congestion predicts cardiac events and mortality in ESRD. J. Am. Soc. Nephrol. 24, 639-646 (2013).
213. Blanco, I., Piccari, L. & Barberà, J. A. Pulmonary vasculature in COPD: the silent component. Respirology 21, 984-994 (2016).
214. Bolignano, D. et al. High estimated pulmonary artery systolic pressure predicts adverse cardiovascular outcomes in stage 2-4 chronic kidney disease. Kidney Int. 88, 130-136 (2015).
215. Navaneethan, S. D. et al. Prevalence, predictors, and outcomes of pulmonary hypertension in CKD. J. Am. Soc. Nephrol. 27, 1-10 (2015).
216. Bolignano, D. et al. Pulmonary hypertension in CKD. Am. J. Kidney Dis. 61, 612-622 (2013).
217. Wang, J. et al. Impact of obstructive sleep apnea syndrome on endothelial function, arterial stiffening, and serum inflammatory markers: an updated metaanalysis and metaregression of 18 studies. J. Am. Heart Assoc. 4, e002454 (2015).
218. Abboud, F. & Kumar, R. Obstructive sleep apnea and insight into mechanisms of sympathetic overactivity. J. Clin. Invest. 124, 1454-1457 (2014).
219. Kholdani, C, Fares, W. H. & Mohsenin, V. Pulmonary hypertension in obstructive sleep apnea: is it clinically significant? A critical analysis of the association and pathophysiology. Pulm. Circ. 5, 220-227 (2015).
220. Ogna, A. et al. Sleep characteristics in early stages of chronic kidney disease in the HypnoLaus Cohort. Sleep 39, 945-953 (2015).
221. Sim, J. J., Rasgon, S. A. & Derose, S. F Review article: managing sleep apnoea in kidney diseases. Nephrology (Carlton). 15, 146-152 (2010).
222. DiBona, G. F Nervous kidney. Interaction between renal sympathetic nerves and the renin-angiotensin system in the control of renal function. Hypertension 36, 1083-1088 (2000).
223. Bourque, C. W., Oliet, S. H. & Richard, D. Osmoreceptors, osmoreception, and osmoregulation. Front. Neuroendocrinol. 15, 231-274 (1994).
224. Stems, R. H. General principles of disorders of water balance (hyponatremia and hypernatremia) and sodium balance (hypovolemia and edema). UpToDate https://www.uptodate.com/contents/general-principles-of-disorders-of-water-balance-hyponatremia-and-hypernatremia-and-sodium-balance-hypovolemia-and-edema (2017).
225. Lechner, S. G. et al. The molecular and cellular identity of peripheral osmoreceptors. Neuron 69, 332-344 (2011).
226. Antunes-Rodrigues, J., de Castro, M., Elias, L. L, Valenca, M. M. & McCann, S. M. Neuroendocrine control body fluid metabolism. Physiol. Rev. 84, 169-208 (2004).
227. Buijs, F N. et al. The circadian system: a regulatory feedback network of periphery and brain. Physiology 31, 170-181 (2016).
228. Peek, C. B. et al. Circadian regulation of cellular physiology. Methods Enzymol. 552, 165-184 (2015).
229. Wuerzner, G., Firsov, D. & Bonny, O. Circadian glomerular function: from physiology to molecular and therapeutical aspects. Nephrol. Dial. Transplant. 29, 1475-1480 (2014).
230. Butterworth, R. F in Basic Neurochemistry: Molecular, Cellular and Medical Aspects 6th edn (eds Siegel, G. J. et al.) (Lippincott-Raven, 1999).
231. Meyer, T. W. & Hostetter, T H. Approaches to uremia. J. Am. Soc. Nephrol. 25, 2151-2158 (2014).
232. Kurella, M. et al. Chronic kidney disease and cognitive impairment in the elderly: the health, aging, and body composition study. J. Am. Soc. Nephrol. 16, 2127-2133 (2005).
233. Seliger, S. L. Moderate renal impairment and risk of dementia among older adults: the Cardiovascular Health Cognition Study. J. Am. Soc. Nephrol. 15, 1904-1911 (2004).
234. Chillon, J.-M., Massy, Z. A. & Stengel, B. Neurological complications in chronic kidney disease patients. Nephrol. Dial. Transplant. 31, 1606-1614 (2015).
235. Sink, K. M. et al. Cerebral structural changes in diabetic kidney disease: African American-Diabetes Heart Study MIND. Diabetes Care 38, 206-212 (2015).
236. Degaspari, S. et al. Altered KLOTHO and NF-KB-TNF-O signaling are correlated with nephrectomy-induced cognitive impairment in rats. PLoS ONE 10, e0125271 (2015).
237. Smith, L. K. et al. (32-microglobulin is a systemic pro-aging factor that impairs cognitive function and neurogenesis. Nat. Med. 21, 932-937 (2015).
238. Vanholder, R. et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int. 63, 1934-1943 (2003).
239. Lee, Y. C. et al. Sleep apnea and the risk of chronic kidney disease: a nationwide population-based cohort study. Sleep 38, 213-221 (2015).
240. Molnar, M. Z. et al. Association of incident obstructive sleep apnoea with outcomes in a large cohort of US veterans. Thorax 70, 888-895 (2015).
241. Calvin, A. D., Albuquerque, F. N., Lopez-Jimenez, F. & Somers, V. K. Obstructive sleep apnea, inflammation, and the metabolic syndrome. Metab. Syndr. Relat. Disord. 7, 271-278 (2009).
242. Zoccali, C. et al. Nocturnal hypoxemia, night-day arterial pressure changes and left ventricular geometry in dialysis patients. Kidney Int. 53, 1078-1084 (1998).
243. Daulatzai, M. A. Evidence of neurodegeneration in obstructive sleep apnea: relationship between obstructive sleep apnea and cognitive dysfunction in the elderly. J. Neurosci. Res. 93, 1778-1794 (2015).
244. Svatikova, A. et al. Serum amyloid a in obstructive sleep apnea. Circulation 108, 1451-1454 (2003).
245. Yaouhi, K. et al. A combined neuropsychological and brain imaging study of obstructive sleep apnea. J. Sleep Res. 18, 36-48 (2009).
246. Moodalbail, D. G. et al. Systematic review of structural and functional neuroimaging findings in children and adults with CKD. Clin. J. Am. Soc. Nephrol. 8, 1429-1448 (2013).
247. Griva, K. et al. Cognitive impairment and 7-year mortality in dialysis patients. Am. J. Kidney Dis. 56, 693-703 (2010).
248. Ahn, A. C., Tewari, M., Poon, C.-S. & Phillips, R. S. The limits of reductionism in medicine: could systems biology offer an alternative? PLoS Med. 3, e208 (2006).
249. National Institutes of Health. What is the BRAIN Initiative? NIH http://www.braininitiative.nih.gov/(2017).
250. Zawada, A. M. et al. Massive analysis of cDNA Ends (MACE) and miRNA expression profiling identifies proatherogenic pathways in chronic kidney disease. Epigenetics 9, 161-172 (2014).
251. Moreno, J. A. et al. The inflammatory cytokines TWEAK and TNFα reduce renal klotho expression through NFκB. J. Am. Soc. Nephrol. 22, 1315-1325 (2011).
252. Schepers, E. et al. Transcriptome analysis in patients with chronic kidney disease on hemodialysis disclosing a key role for CD16+CX3CR1+ monocytes. PLoS ONE 10, e0121750 (2015).
253. Schiffer, E. et al. Markers of vascular disease in plasma from patients with chronic kidney disease identified by proteomic analysis. J. Hypertens. 29, 783-790 (2011).
254. Gajjala, P. R., Fliser, D., Speer, T., Jankowski, V. & Jankowski, J. Emerging role of post-translational modifications in chronic kidney disease and cardiovascular disease. Nephrol. Dial. Transplant. 30, 1814-1824 (2015).
255. Toyohara, T. et al. Metabolomic profiling of uremic solutes in CKD patients. Hypertens. Res. 33, 944-952 (2010).
256. Kalim, S. et al. A plasma long-chain acylcarnitine predicts cardiovascular mortality in incident dialysis patients. J. Am. Heart Assoc. 2, e000542 (2013).
257. Posada-Ayala, M. et al. Identification of a urine metabolomic signature in patients with advanced-stage chronic kidney disease. Kidney Int. 85, 103-111 (2014).
258. Koeth, R. A. et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat. Med. 19, 576-585 (2013).
259. Bain, M. A., Faull, R., Fornasini, G., Milne, R. W. & Evans, A. M. Accumulation of trimethylamine and trimethylamine-N-oxide in end-stage renal disease patients undergoing haemodialysis. Nephrol. Dial. Transplant. 21, 1300-1304 (2006).
260. Duranton, F. et al. Normal and pathologic concentrations of uremic toxins. J. Am. Soc. Nephrol. 23, 1258-1270 (2012).
261. Cisek, K., Krochmal, M., Klein, J. & Mischak, H. The application of multi-omics and systems biology to identify therapeutic targets in chronic kidney disease. Nephrol. Dial. Transplant. 31, 2003-2011 (2015).
262. Green, E. D. et al. Charting a course for genomic medicine from base pairs to bedside. Nature 470, 204-213 (2011).
263. Wanichthanarak, K., Fahrmann, J. F. & Grapov, D. Genomic, proteomic, and metabolomic data integration strategies. Biomark. Insights 10 (Suppl. 4), 1-6 (2015).
264. McMullan, D. What is personalized medicine? GenomeMag http://genomemag.com/what-is-personalized-medicine/# (2016).
265. de Zeeuw, D. et al. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N. Engl. J. Med. 369, 2492-2503 (2013).
266. Guo, S., Zou, J. & Wang, G. Advances in the proteomic discovery of novel therapeutic targets in cancer. Drug Des. Devel. Ther. 7, 1259-1271 (2013).
267. Merchant, M. L. Mass spectrometry in chronic kidney disease research. Adv. Chron. Kidney Dis. 17, 455-468 (2010).
268. Papadopoulos, T. et al. Omics databases on kidney disease: where they can be found and how to benefit from them. Clin. Kidney J. 9, 343-352 (2016).
269. Zoccali, C., Tripepi, G., Dounousi, E. & Mallamaci, F. Chronic kidney disease (CKD) as a systemic disease: whole body autoregulation and inter-organ crosstalk. Kidney Blood Press. Res. 39, 134-141 (2014).
270. Vanholder, R. et al. Clinical management of the uraemic syndrome in chronic kidney disease. lancet. Diabetes Endocrinol. 4, 360-373 (2016).
271. Dhabhar, F. S., Miller, A. H., McEwen, B. S. & Spencer, R. L. Stress-induced changes in blood leukocyte distribution. Role of adrenal steroid hormones. J. Immunol. 157, 1638-1644 (1996).
272. Kohm, A. P. & Sanders, V. M. Norepinephrine and beta 2-adrenergic receptor stimulation regulate CD4+ T and B lymphocyte function in vitro and in vivo. Pharmacol. Rev 53, 487-525 (2001).
273. Lieberman, H. R., Garfield, G., Waldhauser, F., Lynch, H. J. & Wurtman, R. J. Possible behavioral consequences of light-induced changes in melatonin availability. Ann. NY Acad. Sci. 453, 242-252 (1985).
274. Sassin, J. F. et al. Human growth hormone release: relation to slow-wave sleep and sleep-walking cycles. Science 165, 513-515 (1969).
275. Sassin, J. F., Frantz, A. G., Weitzman, E. D. & Kapen, S. Human prolactin: 24-hour pattern with increased release during sleep. Science 177, 1205-1207 (1972).
276. Cernysiov, V., Gerasimcik, N., Mauricas, M. & Girkontaite, I. Regulation of T-cell-independent and T-cell-dependent antibody production by circadian rhythm and melatonin. Int. Immunol. 22, 25-34 (2010).
277. Dimitrov, S., Lange, T., Fehm, H. L. & Born, J. A regulatory role of prolactin, growth hormone, and corticosteroids for human T-cell production of cytokines. Brain. Behav. Immun. 18, 368-374 (2004).
278. Ericsson, A., Arias, C. & Sawchenko, P. E. Evidence for an intramedullary prostaglandin-dependent mechanism in the activation of stress-related neuroendocrine circuitry by intravenous interleukin-1. J. Neurosci. 17, 7166-7179 (1997).
279. Cutolo, M. et al. Circadian rhythms: glucocorticoids and arthritis. Ann. NY Acad. Sci. 1069, 289-299 (2006).
280. Semenza, G. L. Hypoxia-inducible factor 1 and cardiovascular disease. Annu. Rev. Physiol. 76, 39-56 (2014).
281. Thangarajah, H. et al. HIF-1alpha dysfunction in diabetes. Cell Cycle 9, 75-79 (2010).
282. Zhu, X.-Y. et al. Cortical microvascular remodeling in the stenotic kidney: role of increased oxidative stress. Arterioscler. Thromb. Vasc. Biol. 24, 1854-1859 (2004).